IL17A and neoplasm: To assess the effect of the therapies on the anti-tumor-immune response, we assessed expression of IFN-γ and IL-17A marking pro-inflammatory T helper type 1 (TH1) and T helper type 17 (TH17) cells, respectively, and IL-10 marking anti-inflammatory regulatory T cells (Treg) in the tumor mass by real time PCR (Figure 9).